Analysts expect PFSweb, Inc. (NASDAQ:PFSW) to report $0.13 EPS on March, 15.They anticipate $0.05 EPS change or 62.50% from last quarter’s $0.08 EPS. PFSW’s profit would be $2.47M giving it 14.35 P/E if the $0.13 EPS is correct. After having $0.05 EPS previously, PFSweb, Inc.’s analysts see 160.00% EPS growth. The stock decreased 0.40% or $0.03 during the last trading session, reaching $7.46. About 9,262 shares traded. PFSweb, Inc. (NASDAQ:PFSW) has declined 44.08% since February 17, 2017 and is downtrending. It has underperformed by 60.78% the S&P500.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.39 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.
PFSweb, Inc. provides omni-channel commerce solutions in the United States, Europe, Canada, and India. The company has market cap of $141.89 million. It operates through two divisions, PFSweb, and Business and Retail Connect. It currently has negative earnings. The firm offers strategic commerce consulting services, including commerce strategy, digital opportunity audit, organizational/operational readiness, omni-channel consulting, and platform evaluation/selection services; and agency services, such as LiveArea, digital strategy, design, user experience, interactive development, SEO and paid search, affiliate marketing, conversion optimization, storefront management, email marketing, and digital analytics.
Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.12, from 0.71 in 2017Q2. It increased, as 9 investors sold PFSweb, Inc. shares while 15 reduced holdings. 8 funds opened positions while 12 raised stakes. 9.91 million shares or 0.36% more from 9.87 million shares in 2017Q2 were reported. Fincl Bank Of Mellon invested in 65,722 shares or 0% of the stock. 84,375 are held by White Pine Ltd. Bancorporation Of America Corp De reported 0% of its portfolio in PFSweb, Inc. (NASDAQ:PFSW). Tower Capital Ltd (Trc) has invested 0% of its portfolio in PFSweb, Inc. (NASDAQ:PFSW). Deutsche Bank Ag invested 0% of its portfolio in PFSweb, Inc. (NASDAQ:PFSW). Tiaa Cref Investment Management holds 0% or 23,000 shares in its portfolio. Georgia-based Invesco Limited has invested 0% in PFSweb, Inc. (NASDAQ:PFSW). Geode Cap Mgmt Limited Liability has invested 0% in PFSweb, Inc. (NASDAQ:PFSW). Diker Limited Liability owns 31,000 shares. Wellington Mgmt Grp Ltd Liability Partnership has 2.64M shares. Dimensional Fund Advsr Limited Partnership holds 0% or 613,681 shares in its portfolio. Punch & Associate Investment Mngmt owns 337,022 shares for 0.25% of their portfolio. Us-based Ancora Advsrs has invested 0.18% in PFSweb, Inc. (NASDAQ:PFSW). 30,981 are held by Northern Trust. Renaissance Ltd Liability Corporation reported 555,539 shares.
Among 7 analysts covering PFSweb (NASDAQ:PFSW), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. PFSweb had 17 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, November 9 by Northland Capital. The stock has “Buy” rating by Canaccord Genuity on Thursday, June 8. Canaccord Genuity maintained PFSweb, Inc. (NASDAQ:PFSW) on Tuesday, March 15 with “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Sunday, October 1. Craig Hallum downgraded the shares of PFSW in report on Thursday, November 9 to “Hold” rating. Northland Capital maintained the stock with “Buy” rating in Thursday, September 21 report. The company was initiated on Friday, April 15 by Wunderlich. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, August 9. The stock of PFSweb, Inc. (NASDAQ:PFSW) has “Buy” rating given on Tuesday, August 8 by Northland Capital. The rating was initiated by Canaccord Genuity on Thursday, January 21 with “Buy”.
Analysts await Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report earnings on February, 26. They expect $-0.33 earnings per share, down 6.45% or $0.02 from last year’s $-0.31 per share. After $-0.31 actual earnings per share reported by Accelerate Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 6.45% negative EPS growth.
Birchview Capital Lp holds 25.32% of its portfolio in Accelerate Diagnostics, Inc. for 2.18 million shares. Miura Global Management Llc owns 960,000 shares or 5.62% of their US portfolio. Moreover, Selkirk Management Llc has 5.4% invested in the company for 440,000 shares. The Minnesota-based Next Century Growth Investors Llc has invested 1.36% in the stock. Trellus Management Company Llc, a New York-based fund reported 29,186 shares.
The stock increased 1.00% or $0.25 during the last trading session, reaching $25.15. About 406,710 shares traded or 0.78% up from the average. Accelerate Diagnostics, Inc. (AXDX) has risen 147.12% since February 17, 2017 and is uptrending. It has outperformed by 130.42% the S&P500.
Since January 1, 0001, it had 5 insider purchases, and 0 selling transactions for $9.01 million activity.